Jo Klaveness

Professor
ved Farmasøytisk institutt ved Universitetet i Oslo

Resultater Resultater

Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model.

Lien, Vegard Torp; Celen, Sofie; Nuruddin, Syed; Attili, Bala; Doumont, Gilles; Van Simaeys, Gaetan; Bormans, Guy; Klaveness, Jo; Olberg, Dag Erlend. 2021, Nuclear Medicine and Biology. PET-SENTER, KUL, UIO, UldBVitenskapelig artikkel

Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation.

Lien, Vegard Torp; Kristiansen, Margrethe Konstanse; Pettersen, Solveig; Haugen, Mads Haugland; Olberg, Dag Erlend; Waaler, Jo; Klaveness, Jo. 2019, RSC Advances. PET-SENTER, UIO, OUSVitenskapelig artikkel

Synthesis and antiproliferative evaluation of novel N‑arylquinolones.

Lien, Vegard Torp; Olberg, Dag Erlend; Hagelin, Gunnar; Klaveness, Jo. 2019, Monatshefte für Chemie. PET-SENTER, UIOVitenskapelig artikkel

Design, synthesis and biological evaluation of 6‐substituted quinolines derived from cabozantinib as c‐Met inhibitors.

Lien, Vegard Torp; Pettersen, Solveig; Haugen, Mads Haugland; Olberg, Dag Erlend; Mælandsmo, Gunhild Mari; Klaveness, Jo. 2019, Archiv der Pharmazie. PET-SENTER, UIT, UIO, OUSVitenskapelig artikkel

Towards dual inhibitors of c-Met and WNT; synergistic treatment of cancerous diseases.

Kristiansen, Margrethe Konstanse; Lien, Vegard Torp; Klaveness, Jo. 2019, Organisk Kjemisk Vintermøte 2019. UIOPoster

1 - 5 av 73 | Neste | Siste »